tiprankstipranks
Analyst Profile
Followed by 11 other investors
.
Wimal Kapadia

Wimal Kapadia

Bernstein
Wall Street Analyst
Ranked #2,114 out of 8,054 Analysts on TipRanks (#3,980 out of 21,594 overall experts)

Success Rate

60%
49 out of 81 Profitable Transactions

Average Return

7.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Wimal Kapadia's ratings since 2019 and opened each position for the duration of 1 Year:
60.49% of your transactions would have been profitable with an average return of 7.0%

Stock Rating Distribution

136Ratings
75.00% Buy
25.00% Hold
0.00% Sell
Distribution of Wimal Kapadia's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Novo Nordisk A/S (UK)
(0QIU)
Rating Type:Buy
Dates:Oct 30, 2020 - Oct 30, 2021
Gain:72.80%
The most profitable rating made by Wimal Kapadia

Wimal Kapadia's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Novo Nordisk
Mar 05, 2019
Buy
Reiterated
$49.24
(-53.38% Downside)
100%
+21.63%
7
Sanofi-Aventis Sa
Sep 03, 2019
Buy
Initiated
$52.00
(22.53% Upside)
100%
+14.80%
1
Galapagos
Jan 04, 2021
Hold
Reiterated
€85.00
(55.02% Upside)
0.00%
1
0ND5.XX1
H. Lundbeck A/S
Jan 04, 2021
Hold
Reiterated
0.00%
2
Bayer
Jan 04, 2021
Buy
Reiterated
€74.00
(35.13% Upside)
36%
+0.05%
14
UCB SA
Jan 04, 2022
Buy
Reiterated
€110.00
(50.27% Upside)
33%
-10.60%
3
Genmab A/S
Jan 04, 2022
Buy
Reiterated
kr3,200.00
(49.60% Upside)
0.00%
3
Merck KGaA
Jul 13, 2022
Hold
Reiterated
€210.00
(14.13% Upside)
100%
+9.94%
40
Novo Nordisk
Jul 13, 2022
Buy
Reiterated
kr900.00
(15.97% Upside)
84%
+24.37%
22
Roche Holding AG
Jul 21, 2022
Buy
Reiterated
$421.53
(28.64% Upside)
42%
-1.56%
23
List of latest recommendations made by Wimal Kapadia. Click to expand and see Wimal Kapadia's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More